⌕
Halozyme Therapeutics · HALO · Nasdaq
Tenet 71 · Solid
Compare
$95.97−0.55%At closeTenet 71 · Solid
$95.97−0.53 (−0.55%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Halozyme Therapeutics (HALO) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is HALO's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Zacks Investment ResearchNov 17, 2026 · 11:31 ETEARNINGS EXPECTED BY FEB 16
HALO Rallies More Than 40% in 6 Months: How Should You Play the Stock?

Halozyme surges 43.1% in six months on strong ENHANZE-driven royalties and higher revenue guidance.…

HALO −0.5% todayRead at source ↗
● Zacks Investment ResearchNov 11, 2026 · 13:16 ETEARNINGS EXPECTED BY FEB 16
Will HALO's Partner Royalties Drive Growth for the Rest of 2026?

Halozyme's royalty revenues surged 45.8% in the first nine months of 2026, prompting higher guidance.…

HALO −0.5% todayRead at source ↗
● Zacks Investment ResearchNov 10, 2026 · 16:46 ET
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why

Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.…

HALO −0.5% todayRead at source ↗
● Zacks Investment ResearchNov 10, 2026 · 10:41 ET
Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year?

Here is how Halozyme Therapeutics (HALO) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.…

HALO −0.5% todayRead at source ↗
● Zacks Investment ResearchNov 6, 2026 · 13:01 ETEARNINGS EXPECTED BY FEB 16
Halozyme Stock Down Despite Q3 Earnings and Revenue Beat

HALO's Q3 earnings & revenues beat estimates, driven by higher royalties and product sales. The company raises its 2026 outlook, yet shares fall in after-hours.…

HALO −0.5% todayRead at source ↗
● Zacks Investment ResearchNov 6, 2026 · 11:01 ETEARNINGS EXPECTED BY FEB 16
HALO Q3 Earnings Call Highlights Royalty Growth and Patent Dispute

Halozyme lifts its 2026 outlook after a 44% royalty surge, as ENHANZE expansion, Hypercon trials and a Merck patent dispute draw investors' focus.…

HALO −0.5% todayRead at source ↗
● PRNewsWireNov 6, 2026 · 10:04 ETCOMPANY'S OWN WORDS
Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029

SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of th…

HALO −0.5% todayRead at source ↗
● PRNewsWireNov 6, 2026 · 09:57 ET
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer

Approval extends RYBREVANT FASPRO's well-established, dual-targeted benefit beyond lung cancer SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme) today announced that Johnson & …

HALO −0.5% todayRead at source ↗
● MarketBeatNov 6, 2026 · 00:14 ETEARNINGS EXPECTED BY FEB 16
What Halozyme Therapeutics (HALO) Said on Its Q3 Earnings Call

Halozyme Therapeutics NASDAQ: HALO raised its full-year 2026 guidance after reporting record third-quarter revenue and royalties, driven by growth in established partner products and contributions from newer subcutaneous…

HALO −0.5% todayRead at source ↗
● Zacks Investment ResearchNov 5, 2026 · 19:01 ETEARNINGS EXPECTED BY FEB 16
Compared to Estimates, Halozyme Therapeutics (HALO) Q3 Earnings: A Look at Key Metrics

The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates …

HALO −0.5% todayRead at source ↗
● Zacks Investment ResearchNov 5, 2026 · 18:46 ETEARNINGS EXPECTED BY FEB 16
Halozyme Therapeutics (HALO) Tops Q3 Earnings and Revenue Estimates

Halozyme Therapeutics (HALO) came out with quarterly earnings of $2.39 per share, beating the Zacks Consensus Estimate of $2.29 per share. This compares to earnings of $1.72 per share a year ago.…

HALO −0.5% todayRead at source ↗
● PRNewsWireNov 5, 2026 · 16:05 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 16
HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Total Revenue Increased 39% YOY to $493 million Royalty Revenue Increased 44% YOY to $341 million Raising 2026 Financial Guidance Ranges: Total Revenue of $1.860 - $1.925 billion, YOY Growth of 33% - 38% Royalty Revenue …

HALO −0.5% todayRead at source ↗
● Zacks Investment ResearchNov 4, 2026 · 10:16 ETEARNINGS EXPECTED BY FEB 16
Halozyme Therapeutics (HALO) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

Evaluate the expected performance of Halozyme Therapeutics (HALO) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for …

HALO −0.5% todayRead at source ↗
● Zacks Investment ResearchOct 30, 2026 · 10:41 ETEARNINGS EXPECTED BY FEB 16
HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?

Halozyme is poised for a Q3 earnings beat as strong demand for partnered drugs is likely to boost royalties and drive the top line.…

HALO −0.5% todayRead at source ↗
● Zacks Investment ResearchOct 29, 2026 · 11:06 ETEARNINGS EXPECTED BY FEB 16
Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth

Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

HALO −0.5% todayRead at source ↗
● Business WireOct 27, 2026 · 11:53 ET
HALO-Flight Strengthens its Texas-based Air Med Fleet with Additional Bell 407GXi Purchase Order

FORT WORTH, Texas--(BUSINESS WIRE)--AMTC-- Bell Textron Inc., a Textron Inc. (NYSE: TXT) company, announced during the annual Air Medical Transport Conference (AMTC) 2026 the purchase order for a Bell 407GXi to HALO-Flig…

HALO −0.5% todayRead at source ↗
● Defense WorldOct 25, 2026 · 04:36 ETEARNINGS EXPECTED BY FEB 16
11,095 Halozyme Therapeutics, Inc. $HALO Shares Purchased by Gibbs Wealth Management

Gibbs Wealth Management increased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 140.0% in a recent quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned …

HALO −0.5% todayRead at source ↗
● PRNewsWireOct 22, 2026 · 08:30 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 16
Halozyme to Report Third Quarter 2026 Financial and Operating Results

SAN DIEGO, Oct. 22, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its third quarter 2026 financial and operating results on Thursday, November 5, 2026, follo…

HALO −0.5% todayRead at source ↗
● FXEmpireOct 21, 2026 · 07:23 ETEARNINGS EXPECTED BY FEB 16
Halozyme's Strong Earnings Growth Sends Shares Higher

Halozyme Therapeutics, Inc. (HALO) shares are up 910% since March 2014.…

HALO −0.5% todayRead at source ↗
● Defense WorldOct 18, 2026 · 04:41 ETEARNINGS EXPECTED BY FEB 16
Halozyme Therapeutics, Inc. $HALO Stock Position Cut by First Citizens Bank & Trust Co.

First Citizens Bank and Trust Co. decreased its position in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 59.5% during a recent quarter, according to its most recent filing with the Securities and Exchange Commission (SE…

HALO −0.5% todayRead at source ↗
● PRNewsWireOct 7, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets

SAN DIEGO, Oct. 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") announced today that the specialized Dutch patent court of the Hague has found Merck to be infringing one o…

HALO −0.5% todayRead at source ↗
● PRNewsWireOct 6, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology

Expanded agreement increases argenx's exclusive access to ENHANZE® from six to eight targets SAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announce…

HALO −0.5% todayRead at source ↗
● PRNewsWireSep 30, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Halozyme Announces Appointment of Jim Daly to its Board of Directors

SAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of James "Jim" Daly to its Board of Directors.…

HALO −0.5% todayRead at source ↗
● PRNewsWireSep 17, 2026 · 23:20 ETCOMPANY'S OWN WORDS
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033

SAN DIEGO, Sept. 17, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced the pricing of $1.3 billion aggregate principal amount of 1.50% convertible senior notes…

HALO −0.5% todayRead at source ↗
● PRNewsWireSep 16, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033

SAN DIEGO, Sept. 16, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced that it intends to offer, subject to market conditions and other factors, $1.05 billion …

HALO −0.5% todayRead at source ↗

Expected by Feb 16. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just HALO · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.